{"links": [{"source": 0, "target": "t5835", "value": "None"}, {"source": 0, "target": "t5874", "value": "None"}, {"source": 0, "target": "t5931", "value": "None"}, {"source": 0, "target": "t5829", "value": "None"}, {"source": 0, "target": "t5858", "value": "None"}, {"source": 0, "target": "t5890", "value": "None"}, {"source": 0, "target": "t5880", "value": "None"}, {"source": 0, "target": "t5897", "value": "None"}, {"source": 0, "target": "t5913", "value": "None"}, {"source": 0, "target": "t5868", "value": "None"}, {"source": 0, "target": "t5925", "value": "None"}, {"source": 0, "target": "t5848", "value": "None"}, {"source": 0, "target": "t5884", "value": "None"}, {"source": 0, "target": "t5920", "value": "None"}, {"source": 0, "target": "t5840", "value": "None"}, {"source": 0, "target": "t5903", "value": "None"}, {"source": 0, "target": "t5856", "value": "None"}, {"source": "t5835", "target": "t5837", "value": "None"}, {"source": "t5835", "target": "t5836", "value": "None"}, {"source": "t5874", "target": "t5883", "value": "None"}, {"source": "t5874", "target": "t5875", "value": "None"}, {"source": "t5931", "target": "t5936", "value": "None"}, {"source": "t5931", "target": "t5932", "value": "None"}, {"source": "t5829", "target": "t5830", "value": "None"}, {"source": "t5858", "target": "t5859", "value": "None"}, {"source": "t5858", "target": "t5861", "value": "None"}, {"source": "t5858", "target": "t5865", "value": "None"}, {"source": "t5858", "target": "t5866", "value": "None"}, {"source": "t5858", "target": "t5867", "value": "None"}, {"source": "t5890", "target": "t5896", "value": "None"}, {"source": "t5890", "target": "t5891", "value": "None"}, {"source": "t5880", "target": "t5881", "value": "None"}, {"source": "t5880", "target": "d140", "value": "None"}, {"source": "t5897", "target": "t5902", "value": "None"}, {"source": "t5897", "target": "t5898", "value": "None"}, {"source": "t5913", "target": "t5915", "value": "None"}, {"source": "t5913", "target": "t5918", "value": "None"}, {"source": "t5913", "target": "t5919", "value": "None"}, {"source": "t5913", "target": "t5914", "value": "None"}, {"source": "t5868", "target": "t5870", "value": "None"}, {"source": "t5868", "target": "t5872", "value": "None"}, {"source": "t5868", "target": "t5869", "value": "None"}, {"source": "t5868", "target": "t5871", "value": "None"}, {"source": "t5925", "target": "t5927", "value": "None"}, {"source": "t5925", "target": "t5929", "value": "None"}, {"source": "t5925", "target": "t5928", "value": "None"}, {"source": "t5925", "target": "t5926", "value": "None"}, {"source": "t5848", "target": "t5849", "value": "None"}, {"source": "t5848", "target": "t5850", "value": "None"}, {"source": "t5884", "target": "t5889", "value": "None"}, {"source": "t5884", "target": "t5885", "value": "None"}, {"source": "t5920", "target": "t5923", "value": "None"}, {"source": "t5920", "target": "t5921", "value": "None"}, {"source": "t5920", "target": "t5922", "value": "None"}, {"source": "t5840", "target": "t5841", "value": "None"}, {"source": "t5903", "target": "t5904", "value": "None"}, {"source": "t5903", "target": "t5912", "value": "None"}, {"source": "t5856", "target": "t5857", "value": "None"}, {"source": "t5837", "target": "t5838", "value": "None"}, {"source": "t5836", "target": "t5838", "value": "None"}, {"source": "t5875", "target": "t5876", "value": "None"}, {"source": "t5932", "target": "t5933", "value": "None"}, {"source": "t5830", "target": "t5831", "value": "None"}, {"source": "t5830", "target": "t5833", "value": "None"}, {"source": "t5859", "target": "t5860", "value": "None"}, {"source": "t5861", "target": "t5862", "value": "None"}, {"source": "t5891", "target": "t5892", "value": "None"}, {"source": "t5881", "target": "t5882", "value": "None"}, {"source": "t5898", "target": "t5899", "value": "None"}, {"source": "t5915", "target": "t5917", "value": "None"}, {"source": "t5915", "target": "t5916", "value": "None"}, {"source": "t5870", "target": "t5873", "value": "None"}, {"source": "t5872", "target": "t5873", "value": "None"}, {"source": "t5869", "target": "t5873", "value": "None"}, {"source": "t5871", "target": "t5873", "value": "None"}, {"source": "t5927", "target": "t5930", "value": "None"}, {"source": "t5929", "target": "t5930", "value": "None"}, {"source": "t5928", "target": "t5930", "value": "None"}, {"source": "t5926", "target": "t5930", "value": "None"}, {"source": "t5849", "target": "t5851", "value": "None"}, {"source": "t5850", "target": "t5849", "value": "None"}, {"source": "t5885", "target": "t5886", "value": "None"}, {"source": "t5923", "target": "t5924", "value": "None"}, {"source": "t5921", "target": "t5924", "value": "None"}, {"source": "t5922", "target": "t5924", "value": "None"}, {"source": "t5841", "target": "t5843", "value": "None"}, {"source": "t5841", "target": "t5842", "value": "None"}, {"source": "t5841", "target": "d142", "value": "None"}, {"source": "t5841", "target": "d140", "value": "None"}, {"source": "t5841", "target": "d144", "value": "None"}, {"source": "t5841", "target": "d37", "value": "None"}, {"source": "t5841", "target": "d145", "value": "None"}, {"source": "t5904", "target": "t5905", "value": "None"}, {"source": "t5838", "target": "t5839", "value": "None"}, {"source": "t5838", "target": "d46", "value": "None"}, {"source": "t5876", "target": "t5877", "value": "None"}, {"source": "t5933", "target": "t5934", "value": "None"}, {"source": "t5831", "target": "t5833", "value": "None"}, {"source": "t5831", "target": "t5832", "value": "None"}, {"source": "t5833", "target": "t5834", "value": "None"}, {"source": "t5860", "target": "d130", "value": "None"}, {"source": "t5862", "target": "t5863", "value": "None"}, {"source": "t5892", "target": "t5893", "value": "None"}, {"source": "t5899", "target": "t5900", "value": "None"}, {"source": "t5917", "target": "d278", "value": "None"}, {"source": "t5851", "target": "t5852", "value": "None"}, {"source": "t5851", "target": "t5854", "value": "None"}, {"source": "t5851", "target": "t5853", "value": "None"}, {"source": "t5886", "target": "t5887", "value": "None"}, {"source": "t5843", "target": "t5847", "value": "None"}, {"source": "t5843", "target": "t5844", "value": "None"}, {"source": "t5842", "target": "t5846", "value": "None"}, {"source": "t5905", "target": "t5906", "value": "None"}, {"source": "t5877", "target": "t5878", "value": "None"}, {"source": "t5934", "target": "t5935", "value": "None"}, {"source": "t5832", "target": "t5833", "value": "None"}, {"source": "t5863", "target": "t5864", "value": "None"}, {"source": "t5893", "target": "t5894", "value": "None"}, {"source": "t5900", "target": "t5901", "value": "None"}, {"source": "t5900", "target": "d151", "value": "None"}, {"source": "t5900", "target": "d92", "value": "None"}, {"source": "t5852", "target": "t5857", "value": "None"}, {"source": "t5854", "target": "t5855", "value": "None"}, {"source": "t5853", "target": "t5857", "value": "None"}, {"source": "t5887", "target": "t5888", "value": "None"}, {"source": "t5844", "target": "t5845", "value": "None"}, {"source": "t5844", "target": "d130", "value": "None"}, {"source": "t5906", "target": "t5907", "value": "None"}, {"source": "t5878", "target": "t5879", "value": "None"}, {"source": "t5894", "target": "t5895", "value": "None"}, {"source": "t5901", "target": "d331", "value": "None"}, {"source": "t5901", "target": "d151", "value": "None"}, {"source": "t5855", "target": "t5857", "value": "None"}, {"source": "t5845", "target": "t5846", "value": "None"}, {"source": "t5907", "target": "t5908", "value": "None"}, {"source": "t5879", "target": "d151", "value": "None"}, {"source": "t5908", "target": "t5910", "value": "None"}, {"source": "t5908", "target": "t5911", "value": "None"}, {"source": "t5908", "target": "t5909", "value": "None"}], "nodes": [{"category": "disease", "id": 0, "name": "Healthcare-associated_infections", "x": "250", "y": "350", "fixed": "true", "draggable": "true", "value": {"name": "Healthcare-associated_infections"}}, {"category": "treatment", "id": "t5835", "name": "adult with community acquired pneumonia", "draggable": "true", "value": {"name": "adult with community acquired pneumonia", "type": "treatment related", "time": "", "intention": "", "description": "title:adult with community-acquired pneumonia", "drug": {}}}, {"category": "treatment", "id": "t5874", "name": "adult or child undergoing an invasive surgical procedure", "draggable": "true", "value": {"name": "adult or child undergoing an invasive surgical procedure", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:adult or child undergoing an invasive surgical procedure", "drug": {}}}, {"category": "treatment", "id": "t5931", "name": "person with urinary incontinence related to neurological disease", "draggable": "true", "value": {"name": "person with urinary incontinence related to neurological disease", "type": "treatment related", "time": "", "intention": "", "description": "title:person with urinary incontinence related to neurological disease", "drug": {}}}, {"category": "treatment", "id": "t5829", "name": "person with urinary incontinence related to neurological disease", "draggable": "true", "value": {"name": "person with urinary incontinence related to neurological disease", "type": "treatment related", "time": "", "intention": "", "description": "title:person with urinary incontinence related to neurological disease", "drug": {}}}, {"category": "treatment", "id": "t5858", "name": "adult with lower respiratory tract infection", "draggable": "true", "value": {"name": "adult with lower respiratory tract infection", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:adult with lower respiratory tract infection", "drug": {}}}, {"category": "treatment", "id": "t5890", "name": "patient needing a long term urinary catheter", "draggable": "true", "value": {"name": "patient needing a long term urinary catheter", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:patient needing a long-term urinary catheter", "drug": {}}}, {"category": "treatment", "id": "t5880", "name": "wound cleansing, closure and dressing during surgery", "draggable": "true", "value": {"name": "wound cleansing, closure and dressing during surgery", "type": "treatment related", "time": "", "intention": "cefotaxime\ncefotaxime is used to treat many kinds of bacterial infections, including severe or life-threatening forms. cefotaxime is also used to prevent infections in people having surgery.\ncefotaxime may also be used for purposes not listed in this medication guide.\ncan cefotaxime sodium sterile be used for anything besides clinical use?\ncefotaxime sodium inj ip 250 mg is used for?", "description": "title:wound cleansing, closure and dressing during surgeryhead:Wound cleansing, closure and dressing during surgeryDo not use wound irrigation to reduce the risk of surgical site infection.Do not use intracavity lavage to reduce the risk of surgical site infection.Do not use intraoperative skin re-disinfection or topical cefotaxime in abdominal surgery to reduce the risk of surgical site infection.Cover surgical incisions with an appropriate interactive dressing at the end of the operation.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG74", "drug": {}}}, {"category": "treatment", "id": "t5897", "name": "patient with a vascular access device", "draggable": "true", "value": {"name": "patient with a vascular access device", "type": "treatment related", "time": "", "intention": "", "description": "title:patient with a vascular access device", "drug": {}}}, {"category": "treatment", "id": "t5913", "name": "adult or child receiving healthcare", "draggable": "true", "value": {"name": "adult or child receiving healthcare", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:adult or child receiving healthcare", "drug": {}}}, {"category": "treatment", "id": "t5868", "name": "person with urinary incontinence related to neurological disease", "draggable": "true", "value": {"name": "person with urinary incontinence related to neurological disease", "type": "treatment related", "time": "", "intention": "", "description": "title:person with urinary incontinence related to neurological disease", "drug": {}}}, {"category": "treatment", "id": "t5925", "name": "person with bladder storage problems", "draggable": "true", "value": {"name": "person with bladder storage problems", "type": "cancer ralated", "time": "", "intention": "", "description": "title:person with bladder storage problems", "drug": {}}}, {"category": "treatment", "id": "t5848", "name": "person with an identified neurological lower urinary tract dysfunction", "draggable": "true", "value": {"name": "person with an identified neurological lower urinary tract dysfunction", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with an identified neurological lower urinary tract dysfunction", "drug": {}}}, {"category": "treatment", "id": "t5884", "name": "patient having enteral feeding", "draggable": "true", "value": {"name": "patient having enteral feeding", "type": "treatment related", "time": "", "intention": "", "description": "title:patient having enteral feeding", "drug": {}}}, {"category": "treatment", "id": "t5920", "name": "person with stress incontinence", "draggable": "true", "value": {"name": "person with stress incontinence", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with stress incontinence", "drug": {}}}, {"category": "treatment", "id": "t5840", "name": "adult with diagnosed community acquired pneumonia", "draggable": "true", "value": {"name": "adult with diagnosed community acquired pneumonia", "type": "treatment related", "time": "", "intention": "", "description": "title:adult with diagnosed community-acquired pneumonia", "drug": {}}}, {"category": "treatment", "id": "t5903", "name": "adult or child receiving healthcare for which standard infection control precautions apply in primary or community care", "draggable": "true", "value": {"name": "adult or child receiving healthcare for which standard infection control precautions apply in primary or community care", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:adult or child receiving healthcare for which standard infection-control precautions apply in primary or community care", "drug": {}}}, {"category": "treatment", "id": "t5856", "name": "management of intractable, major urinary problems", "draggable": "true", "value": {"name": "management of intractable, major urinary problems", "type": "treatment related", "time": "", "intention": "", "description": "title:management of intractable, major urinary problemshead:Management of intractable, major urinary problemsFor people with neurogenic lower urinary tract dysfunction who have intractable, major problems with urinary tract management, such as incontinence or renal deterioration:  consider ileal conduit diversion (urostomy) and discuss with the person the option of simultaneous cystectomy as prophylaxis against pyocystis.Offer urodynamic investigations before performing surgical treatments for neurogenic lower urinary tract dysfunction.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148", "drug": {}}}, {"category": "treatment", "id": "t5837", "name": "severity assessment in hospital", "draggable": "true", "value": {"name": "severity assessment in hospital", "type": "treatment related", "time": "", "intention": "", "description": "title:severity assessment in hospitalhead:Severity assessment in hospitalFor a definition, see severity assessment.When a diagnosis of community-acquired pneumonia is made at presentation to hospital, determine whether patients are at low, intermediate or high risk of death using the CURB65 score (see below).Use clinical judgement in conjunction with the CURB65 score to guide the management of community-acquired pneumonia, as follows: consider home-based care for patients with a CURB65 score of 0 or 1 consider hospital-based care for patients with a CURB65 score of 2 or more consider intensive care assessment for patients with a CURB65 score of 3 or more.Stratify patients presenting with community-acquired pneumonia into those with low-, moderate- or high-severity disease. The grade of severity will usually correspond to the risk of death.subhead:CURB65 score for mortality risk assessment in hospitalCURB65 score is calculated by giving 1 point for each of the following prognostic features: confusion (abbreviated Mental Test score 8 or less, or new disorientation in person, place or time; for guidance on delirium, see what NICE says on delirium) raised blood urea nitrogen (over 7 mmol/litre) raised respiratory rate (30 breaths per minute or more) low blood pressure (diastolic 60 mmHg or less, or systolic less than 90 mmHg) age 65 years or more.Patients are stratified for risk of death as follows:  0 or 1: low risk (less than 3% mortality risk) 2: intermediate risk (3\u201315% mortality risk) 3 to 5: high risk (more than 15% mortality risk).Score information from defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study (Lim WS, van der Eerden MM, Laing R, et al. 2003).Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.4Mortality risk assessment in hospital using CURB65 scoreSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG191", "drug": {}}}, {"category": "treatment", "id": "t5836", "name": "severity assessment in primary care", "draggable": "true", "value": {"name": "severity assessment in primary care", "type": "treatment related", "time": "", "intention": "", "description": "title:severity assessment in primary carehead:Severity assessment in primary careFor a definition, see severity assessment.When a clinical diagnosis of community-acquired pneumonia is made in primary care, determine whether patients are at low, intermediate or high risk of death using the CRB65 score (see below). Use clinical judgement in conjunction with the CRB65 score to inform decisions about whether patients need hospital assessment as follows: consider home-based care for patients with a CRB65 score of 0 consider hospital assessment for all other patients, particularly those with a CRB65 score of 2 or more.Stratify patients presenting with community-acquired pneumonia into those with low-, moderate- or high-severity disease. The grade of severity will usually correspond to the risk of death.subhead:CRB65 score for mortality risk assessment in primary careCRB65 score is calculated by giving 1 point for each of the following prognostic features: confusion (abbreviated Mental Test score 8 or less, or new disorientation in person, place or time; for guidance on delirium, see what NICE says on delirium) raised respiratory rate (30 breaths per minute or more) low blood pressure (diastolic 60 mmHg or less, or systolic less than 90 mmHg) age 65 years or more.Patients are stratified for risk of death as follows:  0: low risk (less than 1% mortality risk) 1 or 2: intermediate risk (1\u201310% mortality risk) 3 or 4: high risk (more than 10% mortality risk). Score information from defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study (Lim WS, van der Eerden MM, Laing R, et al. 2003).Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.1Mortality risk assessment in primary care using CRB65 scoreSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG191", "drug": {}}}, {"category": "treatment", "id": "t5883", "name": "staff preparation and protection", "draggable": "true", "value": {"name": "staff preparation and protection", "type": "treatment related", "time": "", "intention": "", "description": "title:staff preparation and protectionhead:Staff preparation and protectionsubhead:Hand preparation and decontaminationThe operating team should remove hand jewellery before operations.The operating team should remove artificial nails and nail polish before operations.The operating team should wash their hands prior to the first operation on the list using an aqueous antiseptic surgical solution, with a single-use brush or pick for the nails, and ensure that hands and nails are visibly clean.Before subsequent operations, hands should be washed using either an alcoholic hand rub or an antiseptic surgical solution. If hands are soiled then they should be washed again with an antiseptic surgical solution.subhead:Personal protective equipmentAll staff should wear specific non-sterile theatre wear in all areas where operations are undertaken.Staff wearing non-sterile theatre wear should keep their movements in and out of the operating area to a minimum.The operating team should wear sterile gowns in the operating theatre during the operation.Consider wearing two pairs of sterile gloves when there is a high risk of glove perforation and the consequences of contamination may be serious.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Surgical site infection quality standard4Intraoperative staff practicesSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG74", "drug": {}}}, {"category": "treatment", "id": "t5875", "name": "information for patients and carers", "draggable": "true", "value": {"name": "information for patients and carers", "type": "treatment related", "time": "", "intention": "", "description": "title:information for patients and carershead:Information for patients and carersOffer patients and carers clear, consistent information and advice throughout all stages of their care. This should include the risks of surgical site infections, what is being done to reduce them and how they are managed.Offer patients and carers information and advice on how to care for their wound after discharge.Offer patients and carers information and advice about how to recognise a surgical site infection and who to contact if they are concerned. Use an integrated care pathway for healthcare-associated infections to help communicate this information to both patients and all those involved in their care after discharge.Always inform patients after their operation if they have been given antibiotics.NICE has written information for the public on preventing and treating surgical site infections.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Surgical site infection quality standard5Information and advice on wound careSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG74", "drug": {}}}, {"category": "treatment", "id": "t5936", "name": "patient experience", "draggable": "true", "value": {"name": "patient experience", "type": "treatment related", "time": "", "intention": "", "description": "title:patient experience", "drug": {}}}, {"category": "treatment", "id": "t5932", "name": "assessment", "draggable": "true", "value": {"name": "assessment", "type": "treatment related", "time": "", "intention": "", "description": "title:assessment", "drug": {}}}, {"category": "treatment", "id": "t5830", "name": "clinical history", "draggable": "true", "value": {"name": "clinical history", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:clinical historyhead:Clinical historyWhen assessing lower urinary tract dysfunction in a person with neurological disease, take a clinical history, including information about: urinary tract symptoms neurological symptoms and diagnosis (if known) clinical course of the neurological disease bowel symptoms sexual function comorbidities  use of prescription and other medication and therapies. See what NICE says on multimorbidity.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148", "drug": {}}}, {"category": "treatment", "id": "t5859", "name": "hospital acquired pneumonia", "draggable": "true", "value": {"name": "hospital acquired pneumonia", "type": "treatment related", "time": "", "intention": "", "description": "title:hospital-acquired pneumonia", "drug": {}}}, {"category": "treatment", "id": "t5861", "name": "tests in primary care", "draggable": "true", "value": {"name": "tests in primary care", "type": "treatment related", "time": "", "intention": "", "description": "title:tests in primary carehead:Tests in primary careFor people presenting with symptoms of lower respiratory tract infection in primary care, consider a point of care C-reactive protein test if after clinical assessment a diagnosis of pneumonia has not been made and it is not clear whether antibiotics should be prescribed. Use the results of the C-reactive protein test to guide antibiotic prescribing in people without a clinical diagnosis of pneumonia as follows: Do not routinely offer antibiotic therapy if the C-reactive protein concentration is less than 20 mg/litre. Consider a delayed antibiotic prescription (a prescription for use at a later date if symptoms worsen) if the C-reactive protein concentration is between 20 mg/litre and 100 mg/litre. Offer antibiotic therapy if the C-reactive protein concentration is greater than 100 mg/litre.NICE has published medtech innovation briefings on:  FebriDx for C-reactive protein and Myxovirus resistance protein A testing in primary careAlere Afinion CRP for C-reactive protein testing in primary careQuikRead go for C-reactive protein testing in primary care.See what NICE says on self-limiting respiratory tract and ear infections \u2013 antibiotic prescribing.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG191", "drug": {}}}, {"category": "treatment", "id": "t5865", "name": "service organisation", "draggable": "true", "value": {"name": "service organisation", "type": "treatment related", "time": "", "intention": "", "description": "title:service organisationhead:Service organisationPut in place processes to allow diagnosis (including X-rays) and treatment of community-acquired pneumonia within 4 hours of presentation to hospital.Quality standardsThe following quality statements are relevant to this part of the interactive flowchart.3Chest X-ray and diagnosis within 4 hours of hospital presentation5Antibiotic therapy within 4 hours in hospitalSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG191", "drug": {}}}, {"category": "treatment", "id": "t5866", "name": "antimicrobial stewardship", "draggable": "true", "value": {"name": "antimicrobial stewardship", "type": "treatment related", "time": "", "intention": "", "description": "title:antimicrobial stewardship", "drug": {}}}, {"category": "treatment", "id": "t5867", "name": "patient experience in adult nhs services", "draggable": "true", "value": {"name": "patient experience in adult nhs services", "type": "treatment related", "time": "", "intention": "", "description": "title:patient experience in adult nhs services", "drug": {}}}, {"category": "treatment", "id": "t5896", "name": "staff training", "draggable": "true", "value": {"name": "staff training", "type": "information and support", "time": "", "intention": "", "description": "title:staff traininghead:Staff trainingCommunity and primary healthcare workers must be trained in catheter insertion, including suprapubic catheter replacement and catheter maintenance.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5891", "name": "education of patients and carers", "draggable": "true", "value": {"name": "education of patients and carers", "type": "treatment related", "time": "", "intention": "", "description": "title:education of patients and carershead:Education of patients and carersPatients and carers should be educated about and trained in techniques of hand decontamination, insertion of intermittent catheters where applicable, and catheter management before discharge from hospital. Follow-up training and ongoing support of patients and carers should be available for the duration of long-term catheterisation.Patients managing their own catheters, and their carers, must be educated about the need for hand decontamination before and after manipulation of the catheter, in accordance with the recommendations on hand decontamination.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Infection prevention and control quality standard6Educating people about infection prevention and controlSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5881", "name": "wound cleansing and dressing after surgery", "draggable": "true", "value": {"name": "wound cleansing and dressing after surgery", "type": "treatment related", "time": "", "intention": "", "description": "title:wound cleansing and dressing after surgeryhead:Wound cleansing and dressing after surgerysubhead:CleansingUse sterile saline for wound cleansing up to 48 hours after surgery.Advise patients that they may shower safely 48 hours after surgery.Use tap water for wound cleansing after 48 hours if the surgical wound has separated or has been surgically opened to drain pus.Do not use topical antimicrobial agents for surgical wounds that are healing by primary intention to reduce the risk of surgical site infection.subhead:DressingUse an aseptic non-touch technique for changing or removing surgical wound dressings.Do not use Eusol and gauze, or moist cotton gauze or mercuric antiseptic solutions to manage surgical wounds that are healing by secondary intention.Use an appropriate interactive dressing to manage surgical wounds that are healing by secondary intention.Refer to a tissue viability nurse (or another healthcare professional with tissue viability expertise) for advice on appropriate dressings for the management of surgical wounds that are healing by secondary intention.subhead:Specialist wound care servicesAlthough there is no direct evidence to support the provision of specialist wound care services for managing difficult to heal surgical wounds, a structured approach to care (including preoperative assessments to identify individuals with potential wound healing problems) is required in order to improve overall management of surgical wounds. To support this, enhanced education of healthcare workers, patients and carers, and sharing of clinical expertise will be required.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG74", "drug": {}}}, {"category": "treatment", "id": "t5902", "name": "staff training", "draggable": "true", "value": {"name": "staff training", "type": "information and support", "time": "", "intention": "", "description": "title:staff traininghead:Staff trainingHealthcare workers caring for a patient with a vascular access device should be trained, and assessed as competent, in using and consistently adhering to the infection prevention practices described in these recommendations.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5898", "name": "education of patients and carers", "draggable": "true", "value": {"name": "education of patients and carers", "type": "treatment related", "time": "", "intention": "", "description": "title:education of patients and carershead:Education of patients and carersBefore discharge from hospital, patients and their carers should be taught any techniques they may need to use to prevent infection and safely manage a vascular access deviceFollow-up training and support should be available to patients with a vascular access device and their carers.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Infection prevention and control quality standard6Educating people about infection prevention and controlSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5915", "name": "secondary care", "draggable": "true", "value": {"name": "secondary care", "type": "cancer ralated", "time": "", "intention": "", "description": "title:secondary care", "drug": {}}}, {"category": "treatment", "id": "t5918", "name": "antimicrobial stewardship", "draggable": "true", "value": {"name": "antimicrobial stewardship", "type": "treatment related", "time": "", "intention": "", "description": "title:antimicrobial stewardship", "drug": {}}}, {"category": "treatment", "id": "t5919", "name": "patient experience", "draggable": "true", "value": {"name": "patient experience", "type": "treatment related", "time": "", "intention": "", "description": "title:patient experience", "drug": {}}}, {"category": "treatment", "id": "t5914", "name": "prevention and control of healthcare associated infections in primary and community care", "draggable": "true", "value": {"name": "prevention and control of healthcare associated infections in primary and community care", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:prevention and control of healthcare-associated infections in primary and community care", "drug": {}}}, {"category": "treatment", "id": "t5870", "name": "renal impairment", "draggable": "true", "value": {"name": "renal impairment", "type": "treatment related", "time": "", "intention": "", "description": "title:renal impairmenthead:Renal impairmentDiscuss with the person and/or their family members and carers the increased risk of renal complications (such as kidney stones, hydronephrosis and scarring) in people with neurogenic urinary tract dysfunction (in particular those with spina bifida or spinal cord injury). Tell them the symptoms to look out for (such as loin pain, urinary tract infection and haematuria) and when to see a healthcare professional.When discussing treatment options, tell the person that indwelling urethral catheters may be associated with higher risks of renal complications (such as kidney stones and scarring) than other forms of bladder management (such as intermittent self catheterisation).Use renal imaging to investigate symptoms that suggest upper urinary tract disease.See what NICE says on chronic kidney disease.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148", "drug": {}}}, {"category": "treatment", "id": "t5872", "name": "bladder cancer", "draggable": "true", "value": {"name": "bladder cancer", "type": "treatment related", "time": "", "intention": "", "description": "title:bladder cancerhead:Bladder cancerDiscuss with the person and/or family members and carers that there may be an increased risk of bladder cancer in people with neurogenic lower urinary tract dysfunction, in particular those with a long history of neurogenic lower urinary tract dysfunction and complicating factors, such as recurrent urinary tract infections. Tell them the symptoms to look out for (especially haematuria) that mean they should see a healthcare professional.Arrange urgent (within 2 weeks) investigation with urinary tract imaging and cystoscopy for people with: visible haematuria or increased frequency of urinary tract infections or  other unexplained lower urinary tract symptoms.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148", "drug": {}}}, {"category": "treatment", "id": "t5869", "name": "preventing urinary tract infection", "draggable": "true", "value": {"name": "preventing urinary tract infection", "type": "treatment related", "time": "", "intention": "", "description": "title:preventing urinary tract infectionhead:Preventing urinary tract infectionDo not routinely use antibiotic prophylaxis for urinary tract infections in people with neurogenic lower urinary tract dysfunction.Consider antibiotic prophylaxis for people who have a recent history of frequent or severe urinary tract infections. Before prescribing antibiotic prophylaxis for urinary tract infection: investigate the urinary tract for an underlying treatable cause (such as urinary tract stones or incomplete bladder emptying) take into account and discuss with the person the risks and benefits of prophylaxis refer to local protocols approved by a microbiologist or discuss suitable regimens with a microbiologist. Ensure that the need for ongoing prophylaxis in all people who are receiving antibiotic prophylaxis is regularly reviewed. When changing catheters in people with a long-term indwelling urinary catheter: do not offer antibiotic prophylaxis routinely consider antibiotic prophylaxisAt the time of publication (August 2012), no antibiotics had a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the GMC s Good practice in prescribing medicines - guidance for doctors for further information. for people who: have a history of symptomatic urinary tract infection after catheter change or experience traumaTrauma is defined as frank haematuria after catheterisation or two or more attempts of catheterisation. during catheterisation.See what NICE says on antimicrobial stewardship.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148CG139", "drug": {}}}, {"category": "treatment", "id": "t5871", "name": "bladder stones", "draggable": "true", "value": {"name": "bladder stones", "type": "treatment related", "time": "", "intention": "", "description": "title:bladder stoneshead:Bladder stonesDiscuss with the person and/or their family members and carers the increased risk of bladder stones in people with neurogenic lower urinary tract dysfunction. Tell them the symptoms to look out for that mean they should see a healthcare professional (for example, recurrent infection, recurrent catheter blockages or haematuria).Discuss with the person and/or their family members and carers that indwelling catheters (urethral and suprapubic) are associated with a higher incidence of bladder stones compared with other forms of bladder management. Tell them the symptoms to look out for that mean they should see a healthcare professional (for example, recurrent infection, recurrent catheter blockages or haematuria).Refer people with symptoms that suggest the presence of bladder stones (for example, recurrent catheter blockages, recurrent urinary tract infection or haematuria) for cystoscopy.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.3Referring men with upper urinary tract infectionsSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148", "drug": {}}}, {"category": "treatment", "id": "t5927", "name": "antimuscarinic drug treatment", "draggable": "true", "value": {"name": "antimuscarinic drug treatment", "type": "treatment related", "time": "", "intention": "", "description": "title:antimuscarinic drug treatmenthead:Antimuscarinic drug treatmentOffer antimuscarinicAt the time of publication (August 2012) not all antimuscarinics had a UK marketing authorisation for this indication or for use in both adults and children. The prescriber should follow relevant professional guidance when prescribing a drug without a marketing authorisation for this indication, taking full responsibility for the decision. Informed consent should be obtained and documented. See the GMC s Good practice in prescribing medicines - guidance for doctors for further information. drugs to people with: spinal cord disease (for example, spinal cord injury or multiple sclerosis) and symptoms of an overactive bladder such as increased frequency, urgency and incontinence. Consider antimuscarinic drug treatment in people with: conditions affecting the brain (for example, cerebral palsy, head injury or stroke) and  symptoms of an overactive bladder. Consider antimuscarinic drug treatment in people with urodynamic investigations showing impaired bladder storage.Monitor residual urine volume in people who are not using intermittent or indwelling catheterisation after starting antimuscarinic treatment. When prescribing antimuscarinics, take into account that:   antimuscarinics known to cross the blood-brain barrier (for example, oxybutynin) have the potential to cause central nervous system-related side effects (such as confusion)  antimuscarinic treatment can reduce bladder emptying, which may increase the risk of urinary tract infections antimuscarinic treatment may precipitate or exacerbate constipation. SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148", "drug": {}}}, {"category": "treatment", "id": "t5929", "name": "bladder wall injection with botulinum toxin type a", "draggable": "true", "value": {"name": "bladder wall injection with botulinum toxin type a", "type": "treatment related", "time": "", "intention": "", "description": "title:bladder wall injection with botulinum toxin type ahead:Bladder wall injection with botulinum toxin type AOffer bladder wall injection with botulinum toxin type AAt the time of publication (August 2012), botulinum toxin type A did not have UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the GMC s Good practice in prescribing medicines - guidance for doctors for further information.  to adults: with spinal cord disease (for example, spinal cord injury and multiple sclerosis) and with symptoms of an overactive bladder and  in whom antimuscarinic drugs have proved to be ineffective or poorly tolerated.Consider bladder wall injection with botulinum toxin type A for children and young people: with spinal cord disease and  with symptoms of an overactive bladder and in whom antimuscarinic drugs have proved to be ineffective or poorly tolerated.Offer bladder wall injection with botulinum toxin type A to adults: with spinal cord disease and with urodynamic investigations showing impaired bladder storage and in whom antimuscarinic drugs have proved to be ineffective or poorly tolerated.Consider bladder wall injection with botulinum toxin type A for children and young people: with spinal cord disease and  with urodynamic investigations showing impaired bladder storage and in whom antimuscarinic drugs have proved to be ineffective or poorly tolerated.Before offering bladder wall injection with botulinum toxin type A: explain to the person and/or their family members and carers that a catheterisation regimen is needed in most people with neurogenic lower urinary tract dysfunction after treatment and  ensure that they are able and willing to manage such a regimen should urinary retention develop after the treatment.Monitor residual urine volume in people who are not using a catheterisation regimen during treatment with botulinum toxin type A.Monitor the upper urinary tract in people who are judged to be at risk of renal complications (for example, those with high intravesical pressures on filling cystometry) during treatment with botulinum toxin type A.Ensure that people who have been offered continuing treatment with repeated botulinum toxin type A injections have prompt access to repeat injections when symptoms return.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148", "drug": {}}}, {"category": "treatment", "id": "t5928", "name": "augmentation cystoplasty", "draggable": "true", "value": {"name": "augmentation cystoplasty", "type": "treatment related", "time": "", "intention": "", "description": "title:augmentation cystoplastyhead:Augmentation cystoplastyConsider augmentation cystoplasty using an intestinal segment for people: with non-progressive neurological disorders and  complications of impaired bladder storage (for example, hydronephrosis or incontinence) and only after a thorough clinical and urodynamic assessment and discussion with the patient and/or their family members and carers about complications, risks and alternative treatments. Offer patients life-long follow up after augmentation cystoplasty because of the risk of long-term complications. Potential complications include metabolic effects, such as the development of vitamin B12 deficiency, and the development of bladder cancer.Offer urodynamic investigations before performing surgical treatments for neurogenic lower urinary tract dysfunction.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148", "drug": {}}}, {"category": "treatment", "id": "t5926", "name": "behavioural management programmes", "draggable": "true", "value": {"name": "behavioural management programmes", "type": "treatment related", "time": "", "intention": "", "description": "title:behavioural management programmeshead:Behavioural management programmesConsider a behavioural management programme (for example, timed voiding, bladder retraining or habit retraining) for people with neurogenic lower urinary tract dysfunction: only after assessment by a healthcare professional trained in the assessment of people with neurogenic lower urinary tract dysfunction and in conjunction with education about lower urinary tract function for the person and/or their family members and carers. When choosing a behavioural management programme, take into account that prompted voiding and habit retraining are particularly suitable for people with cognitive impairment.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148", "drug": {}}}, {"category": "treatment", "id": "t5849", "name": "assessment of factors affecting management", "draggable": "true", "value": {"name": "assessment of factors affecting management", "type": "treatment related", "time": "", "intention": "", "description": "title:assessment of factors affecting managementhead:Assessment of factors affecting managementAssess the impact of the underlying neurological disease on factors that will affect how lower urinary tract dysfunction can be managed, such as: mobility hand function cognitive function social support lifestyle.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148", "drug": {}}}, {"category": "treatment", "id": "t5850", "name": "support for young person transferring from child to adult services", "draggable": "true", "value": {"name": "support for young person transferring from child to adult services", "type": "treatment related", "time": "", "intention": "", "description": "title:support for young person transferring from child to adult serviceshead:Support for young person transferring from child to adult servicesWhen managing the transition of a person from paediatric services to adult services for ongoing care of neurogenic lower urinary tract dysfunction: formulate a clear structured care pathway at an early stage and involve the person and/or their parents and carers involve the young person s parents and carers when preparing transfer documentation with the young person s consent provide a full summary of the person s clinical history, investigation results and details of treatments for the person and receiving clinician integrate information from the multidisciplinary health team into the transfer documentation identify and plan the urological services that will need to be continued after the transition of care formally transfer care to a named individual(s). When receiving a person from paediatric services to adult services for ongoing care of neurogenic lower urinary tract dysfunction: review the transfer documentation and liaise with the other adult services involved in ongoing care (for example, adult neuro-rehabilitation services) provide the person with details of the service to which care is being transferred, including contact details of key personnel, such as the urologist and specialist nurses ensure that urological services are being provided after transition to adult services.Consider establishing regular multidisciplinary team meetings for paediatric and adult specialists to discuss the management of neurogenic lower urinary tract dysfunction in children and young people during the years leading up to transition and after entering adult services. For further information, see what NICE says on transition from children s to adults  services.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148", "drug": {}}}, {"category": "treatment", "id": "t5889", "name": "staff training", "draggable": "true", "value": {"name": "staff training", "type": "information and support", "time": "", "intention": "", "description": "title:staff traininghead:Staff trainingHealthcare workers should be trained in enteral feeding and management of the administration system.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5885", "name": "education of patients and carers", "draggable": "true", "value": {"name": "education of patients and carers", "type": "treatment related", "time": "", "intention": "", "description": "title:education of patients and carershead:Education of patients and carersPatients and carers should be educated about and trained in the techniques of hand decontamination, enteral feeding and the management of the administration system before being discharged from hospital.Follow-up training and ongoing support of patients and carers should be available for the duration of home enteral tube feeding.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Infection prevention and control quality standard6Educating people about infection prevention and controlSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5923", "name": "surgery to insert an artificial urinary sphincter", "draggable": "true", "value": {"name": "surgery to insert an artificial urinary sphincter", "type": "treatment related", "time": "", "intention": "", "description": "title:surgery to insert an artificial urinary sphincterhead:Surgery to insert an artificial urinary sphincterConsider surgery to insert an artificial urinary sphincter for people with neurogenic stress urinary incontinence only if an alternative procedure, such as insertion of an autologous fascial sling, is less likely to control incontinence. Offer urodynamic investigations before performing surgical treatments for neurogenic lower urinary tract dysfunction.When considering inserting an artificial urinary sphincter:   discuss with the person and/or their family members and carers the risks associated with the device, the possible need for repeat operations and alternative procedures ensure that the bladder has adequate low-pressure storage capacity. Monitor the upper urinary tract after artificial urinary sphincter surgery (for example, using annual ultrasound scans), as bladder storage function can deteriorate in some people after treatment of their neurogenic stress incontinence.See what NICE says on preoperative tests.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148", "drug": {}}}, {"category": "treatment", "id": "t5921", "name": "pelvic floor muscle training", "draggable": "true", "value": {"name": "pelvic floor muscle training", "type": "treatment related", "time": "", "intention": "", "description": "title:pelvic floor muscle traininghead:Pelvic floor muscle trainingConsider pelvic floor muscle training for people with: lower urinary tract dysfunction due to multiple sclerosis or stroke or other neurological conditions where the potential to voluntarily contract the pelvic floor is preserved.Select patients for this training after specialist pelvic floor assessment and consider combining treatment with biofeedback and/or electrical stimulation of the pelvic floor.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148", "drug": {}}}, {"category": "treatment", "id": "t5922", "name": "urethral tape and sling surgery", "draggable": "true", "value": {"name": "urethral tape and sling surgery", "type": "treatment related", "time": "", "intention": "", "description": "title:urethral tape and sling surgeryhead:Urethral tape and sling surgeryConsider autologous fascial sling surgery for people with neurogenic stress incontinence. Offer urodynamic investigations before performing surgical treatments for neurogenic lower urinary tract dysfunction.Do not routinely use synthetic tapes and slings in people with neurogenic stress incontinence because of the risk of urethral erosion.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148", "drug": {}}}, {"category": "treatment", "id": "t5841", "name": "pharmacological therapy", "draggable": "true", "value": {"name": "pharmacological therapy", "type": "treatment related", "time": "", "intention": "ceftriaxone\nit is used to treat or prevent bacterial infections.", "description": "title:pharmacological therapyhead:Pharmacological therapysubhead:Antibiotic therapyOffer antibiotic therapy as soon as possible after diagnosis, and certainly within 4 hours to all patients with community-acquired pneumonia who are admitted to hospital.Low-severity community-acquired pneumoniaOffer a 5-day course of a single antibiotic to patients with low-severity community-acquired pneumonia.Consider amoxicillin in preference to a macrolide or a tetracycline for patients with low-severity community-acquired pneumonia. Consider a macrolide or a tetracycline for patients who are allergic to penicillin.Consider extending the course of the antibiotic for longer than 5 days as a possible management strategy for patients with low-severity community-acquired pneumonia whose symptoms do not improve as expected after 3 days. Explain to patients with low-severity community-acquired pneumonia treated in the community, and when appropriate their families or carers, that they should seek further medical advice if their symptoms do not begin to improve within 3 days of starting the antibiotic, or earlier if their symptoms are worsening.Do not routinely offer patients with low-severity community-acquired pneumonia: a fluoroquinolone  dual antibiotic therapy.Moderate- and high-severity community-acquired pneumoniaConsider a 7- to 10-day course of antibiotic therapy for patients with moderate- or high-severity community-acquired pneumonia.Consider dual antibiotic therapy with amoxicillin and a macrolide for patients with moderate-severity community-acquired pneumonia.Consider dual antibiotic therapy with a beta-lactamase stable beta-lactam and a macrolide for patients with high-severity community-acquired pneumonia. Available beta-lactamase stable beta-lactams include: co-amoxiclav, cefotaxime, ceftaroline fosamil, ceftriaxone, cefuroxime and piperacillin with tazobactam.subhead:Glucocorticosteroid treatmentDo not routinely offer a glucocorticosteroid to patients with community-acquired pneumonia unless they have other conditions for which glucocorticosteroid treatment is indicated.Quality standardsThe following quality statements are relevant to this part of the interactive flowchart.2Antibiotic therapy for diagnosed low-severity community-acquired pneumonia5Antibiotic therapy within 4 hours in hospitalSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG191", "drug": {}}}, {"category": "treatment", "id": "t5904", "name": "availability of equipment", "draggable": "true", "value": {"name": "availability of equipment", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:availability of equipmenthead:Availability of equipment Wherever care is delivered, healthcare workers must have available appropriate supplies of the following, in accordance with current health and safety legislation:  materials for hand decontamination sharps containers personal protective equipment.Current health and safety legislation includes (at the time of publication of the recommendations [March 2012]): Health and Safety at Work Act 1974, Management of Health and Safety at Work Regulations 1999, Health and Safety Regulations 2002, Control of Substances Hazardous to Health Regulations 2002, Personal Protective Equipment Regulations 2002 and Health and Social Care Act 2008.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5912", "name": "staff training", "draggable": "true", "value": {"name": "staff training", "type": "information and support", "time": "", "intention": "", "description": "title:staff traininghead:Staff trainingEveryone involved in providing care should be:  educated about the standard principles of infection prevention and control and trained in hand decontamination, the use of personal protective equipment, and the safe use and disposal of sharps.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5857", "name": "possible complications", "draggable": "true", "value": {"name": "possible complications", "type": "treatment related", "time": "", "intention": "", "description": "title:possible complications", "drug": {}}}, {"category": "treatment", "id": "t5838", "name": "microbiological tests", "draggable": "true", "value": {"name": "microbiological tests", "type": "treatment related", "time": "", "intention": "antifungal\nthis medicine is used to treat vaginal yeast infections.", "description": "title:microbiological testshead:Microbiological testsDo not routinely offer microbiological tests to patients with low-severity community-acquired pneumonia.For patients with moderate- or high-severity community-acquired pneumonia: take blood and sputum cultures and consider pneumococcal and legionella urinary antigen tests.subhead:Tests for rapidly identifying bloodstream bacteria and fungiThe following recommendations are from NICE diagnostics guidance on tests for rapidly identifying bloodstream bacteria and fungi (LightCycler SeptiFast Test MGRADE, SepsiTest and IRIDICA BAC BSI assay).There is currently insufficient evidence to recommend the routine adoption in the NHS of the LightCycler SeptiFast Test MGRADE, SepsiTest and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi. The tests show promise and further research to provide robust evidence is encouraged, particularly to demonstrate the value of using the test results in clinical decision-making (see sections\u00a05.18 to\u00a05.22 of NICE diagnostics guidance 20).NICE has published a medtech innovation briefing on Fungitell for antifungal treatment stratification.subhead:Procalcitonin testing for diagnosing and monitoring sepsisThe following recommendations are from NICE diagnostics guidance on procalcitonin testing for diagnosing and monitoring sepsis.The procalcitonin tests (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay or VIDAS BRAHMS PCT assay) show promise but there is currently insufficient evidence to recommend their routine adoption in the NHS. Further research on procalcitonin tests is recommended for guiding decisions to: stop antibiotic treatment in people with confirmed or highly suspected sepsis in the intensive care unit or start and stop antibiotic treatment in people with suspected bacterial infection presenting to the emergency department.Centres currently using procalcitonin tests to guide these decisions are encouraged to participate in research and data collection (see section 6.25 of NICE diagnostics guidance 18).See what NICE says on sepsis.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG191DG20DG18", "drug": {}}}, {"category": "treatment", "id": "t5876", "name": "patient preparation", "draggable": "true", "value": {"name": "patient preparation", "type": "treatment related", "time": "", "intention": "", "description": "title:patient preparationhead:Patient preparationAdvise patients to shower or have a bath (or help patients to shower, bath or bed bath) using soap, either the day before, or on the day of, surgery.Give patients specific theatre wear that is appropriate for the procedure and clinical setting, and that provides easy access to the operative site and areas for placing devices, such as intravenous cannulas. Consider also the patient s comfort and dignity. Do not use hair removal routinely to reduce the risk of surgical site infection.If hair has to be removed, use electric clippers with a single-use head on the day of surgery. Do not use razors for hair removal, because they increase the risk of surgical site infection. Do not use nasal decontamination with topical antimicrobial agents aimed at eliminating Staphylococcus aureus routinely to reduce the risk of surgical site infection. Do not use mechanical bowel preparation routinely to reduce the risk of surgical site infection.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Surgical site infection quality standard1Personal preparation for surgerySourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG74", "drug": {}}}, {"category": "treatment", "id": "t5933", "name": "management", "draggable": "true", "value": {"name": "management", "type": "treatment related", "time": "", "intention": "", "description": "title:management", "drug": {}}}, {"category": "treatment", "id": "t5831", "name": "physical and neurological examination", "draggable": "true", "value": {"name": "physical and neurological examination", "type": "information and support", "time": "", "intention": "", "description": "title:physical and neurological examinationhead:Physical and neurological examinationUndertake a general physical examination that includes: measuring blood pressure an abdominal examination an external genitalia examination a vaginal or rectal examination if clinically indicated (for example, to look for evidence of pelvic floor prolapse, faecal loading or alterations in anal tone). Carry out a focused neurological examination, which may need to include assessment of: cognitive function ambulation and mobility hand function lumbar and sacral spinal segment function.Be aware that unexplained changes in neurological symptoms (for example, confusion or worsening spasticity) can be caused by urinary tract disease, and consider further urinary tract investigation and treatment if this is suspected.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148", "drug": {}}}, {"category": "treatment", "id": "t5833", "name": "when to refer for urgent or specialist investigation", "draggable": "true", "value": {"name": "when to refer for urgent or specialist investigation", "type": "treatment related", "time": "", "intention": "", "description": "title:when to refer for urgent or specialist investigationhead:When to refer for urgent or specialist investigationRefer people for urgent investigation if they have any of the following  red flag  signs and symptoms: haematuria recurrent urinary tract infections (for example, three or more infections in the last 6 months) loin pain recurrent catheter blockages (for example, catheters blocking within 6 weeks of being changed) hydronephrosis or kidney stones on imaging biochemical evidence of renal deterioration.Refer people with changes in urinary function that may be due to new or progressing neurological disease needing specialist investigation (for example, syringomyelia, hydrocephalus, multiple system atrophy or cauda equina syndrome).Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.3Referring men with upper urinary tract infectionsSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148", "drug": {}}}, {"category": "treatment", "id": "t5860", "name": "management of hospital acquired pneumonia", "draggable": "true", "value": {"name": "management of hospital acquired pneumonia", "type": "treatment related", "time": "", "intention": "carbon dioxide\n", "description": "title:management of hospital-acquired pneumoniahead:Management of hospital-acquired pneumoniasubhead:Antibiotic therapyOffer antibiotic therapy as soon as possible after diagnosis, and certainly within 4 hours, to patients with hospital-acquired pneumonia.Choose antibiotic therapy in accordance with local hospital policy (which should take into account knowledge of local microbial pathogens) and clinical circumstances for patients with hospital-acquired pneumonia.Consider a 5- to 10-day course of antibiotic therapy for patients with hospital-acquired pneumonia.NICE has published evidence summaries on: antimicrobial prescribing: Ceftazidime/avibactam hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin.See what NICE says on acutely ill patients in hospital and prevention and control of healthcare-associated infections.Severe acute respiratory failureNICE has published interventional procedures guidance on the following procedures with special arrangements for consent, audit and clinical governance: extracorporeal membrane carbon dioxide removal for acute respiratory failure extracorporeal membrane oxygenation for severe acute respiratory failure in adults.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG191", "drug": {}}}, {"category": "treatment", "id": "t5862", "name": "community acquired pneumonia", "draggable": "true", "value": {"name": "community acquired pneumonia", "type": "treatment related", "time": "", "intention": "", "description": "title:community-acquired pneumonia", "drug": {}}}, {"category": "treatment", "id": "t5892", "name": "assessment and review", "draggable": "true", "value": {"name": "assessment and review", "type": "treatment related", "time": "", "intention": "", "description": "title:assessment and reviewhead:Assessment and reviewIndwelling urinary catheters should be used only after alternative methods of management have been considered. The patient s clinical need for catheterisation should be reviewed regularly and the urinary catheter removed as soon as possible.Catheter insertion, changes and care should be documented.Following assessment, select the best approach to catheterisation that takes account of clinical need, anticipated duration of catheterisation, patient preference and risk of infection.Intermittent catheterisation should be used in preference to an indwelling catheter if it is clinically appropriate and a practical option for the patient.Select the type and gauge of an indwelling urinary catheter based on an assessment of the patient s individual characteristics, including:  age any allergy or sensitivity to catheter materials gender history of symptomatic urinary tract infection patient preference and comfort previous catheter history reason for catheterisation.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Infection prevention and control quality standard4Urinary cathetersSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5882", "name": "treatment of surgical site infection or treatment failure", "draggable": "true", "value": {"name": "treatment of surgical site infection or treatment failure", "type": "treatment related", "time": "", "intention": "", "description": "title:treatment of surgical site infection or treatment failurehead:Treatment of surgical site infection or treatment failureWhen surgical site infection is suspected (i.e. cellulitis), either de novo or because of treatment failure, give the patient an antibiotic that covers the likely causative organisms. Consider local resistance patterns and the results of microbiological tests in choosing an antibiotic.Do not use Eusol and gauze, or dextranomer or enzymatic treatments for debridement in the management of surgical site infection.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Surgical site infection quality standard6Treatment of surgical site infectionSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG74", "drug": {}}}, {"category": "treatment", "id": "t5899", "name": "general asepsis", "draggable": "true", "value": {"name": "general asepsis", "type": "treatment related", "time": "", "intention": "", "description": "title:general asepsishead:General asepsisHands must be decontaminated (see hand decontamination) before accessing or dressing a vascular access device.An aseptic technique must be used for vascular access device catheter site care and when accessing the system. Aseptic Non Touch Technique (ANTT\u2122) is an example of an aseptic technique for vascular access device maintenance, which is widely used in acute and community settings and represents a possible framework for establishing standardised guidance on aseptic technique.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Infection prevention and control quality standard5Vascular access devicesSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5917", "name": "local strategy", "draggable": "true", "value": {"name": "local strategy", "type": "information and support", "time": "", "intention": "excel\n", "description": "title:local strategyhead:Local strategyNICE, in partnership with the Health Protection Agency (HPA), has published the following  measures of excellence in infection prevention and control, at a management or organisational level. This guidance is for board members working in (or with) hospitals.subhead:Board-level leadershipTrust boards demonstrate leadership in infection prevention and control to ensure a culture of continuous quality improvement and to minimise risk to patients.subhead:Be a learning organisationTrusts use information from a range of sources to inform and drive continuous quality improvement to minimise risk from infection.subhead:Healthcare-associated infections surveillance Trusts have a surveillance system in place to routinely gather data and to carry out mandatory monitoring of HCAIs and other infections of local relevance to inform the local response to HCAIs.subhead:Workforce capacity and capabilityTrusts prioritise the need for a skilled, knowledgeable and healthy workforce that delivers continuous quality improvement to minimise the risk from infections. This includes support staff, volunteers, agency/locum staff and those employed by contractors.subhead:Environmental cleanliness Trusts ensure standards of environmental cleanliness are maintained and improved beyond current national guidance.subhead:Multi-agency workingTrusts work proactively in multi-agency collaborations with other local health and social care providers to reduce risk from infection.subhead:Communication Trusts ensure there is clear communication with all staff, patients and carers throughout the care pathway about HCAIs, infection risks and how to prevent HCAIs, to reduce harm from infection.subhead:Admission, discharge and transfer Trusts have a multi-agency patient admission, discharge and transfer policy which gives clear, relevant guidance to local health and social care providers on the critical steps to take to minimise harm from infection.subhead:Patient and public involvement Trusts use input from local patient and public experience for continuous quality improvement to minimise harm from HCAIs.subhead:Trust estate management Trusts consider infection prevention and control when procuring, commissioning, planning, designing and completing new and refurbished hospital services and facilities (and during subsequent routine maintenance).subhead:New technology and innovation Trusts regularly review evidence-based assessments of new technology and other innovations to minimise harm from HCAIs and antimicrobial resistance.For more information about how these measures of excellence can be used in practice, see the NICE guideline on healthcare-associated infections: prevention and control.NICE has written information for people visiting, or receiving treatment in, NHS hospitals on the prevention and control of healthcare-associated infections.Quality standardsThe following quality statements are relevant to this part of the interactive flowchart.Healthcare-associated infections quality standard1Surveillance2Collaborative action3Responsibilities of hospital staff4Planning, design and management of hospital facilities5Admission, discharge and transferInfection prevention and control quality standard2Organisational responsibilitySurgical site infection quality standard7Surveillance \u2013 surgical site infectionSourcesThe NICE guidance that was used to create this part of the interactive flowchart. PH36", "drug": {}}}, {"category": "treatment", "id": "t5916", "name": "preventing and treating surgical site infections", "draggable": "true", "value": {"name": "preventing and treating surgical site infections", "type": "treatment related", "time": "", "intention": "", "description": "title:preventing and treating surgical site infections", "drug": {}}}, {"category": "treatment", "id": "t5873", "name": "monitoring and surveillance", "draggable": "true", "value": {"name": "monitoring and surveillance", "type": "treatment related", "time": "", "intention": "", "description": "title:monitoring and surveillance", "drug": {}}}, {"category": "treatment", "id": "t5930", "name": "possible complications", "draggable": "true", "value": {"name": "possible complications", "type": "treatment related", "time": "", "intention": "", "description": "title:possible complications", "drug": {}}}, {"category": "treatment", "id": "t5851", "name": "information and support", "draggable": "true", "value": {"name": "information and support", "type": "information and support", "time": "", "intention": "", "description": "title:information and supporthead:Information and supportOffer people with neurogenic urinary tract dysfunction, their family members and carers specific information and training. Ensure that people who are starting to use, or are using, a bladder management system that involves the use of catheters, appliances or pads: receive training, support and review from healthcare professionals who are trained to provide support in the relevant bladder management systems and are knowledgeable about the range of products available have access to a range of products that meet their needs have their products reviewed, at a maximum of 2 yearly intervals.Tailor information and training to the person s physical condition and cognitive function to promote their active participation in care and self-management.Inform people how to access further support and information from a healthcare professional about their urinary tract management.Provide contact details for the provision of specialist advice if a person has received care for neurogenic lower urinary tract dysfunction in a specialised setting (for example, in a spinal injury unit or a paediatric urology unit). The contact details should be given to the person and/or their family members and carers and to the non-specialist medical and nursing staff involved in their care.Provide people with neurogenic lower urinary tract dysfunction, and/or their family members and carers with written information that includes: a list of key healthcare professionals involved in their care, a description of their role and their contact details  copies of all clinical correspondence a list of prescribed medications and equipment.This information should also be sent to the person s GP.NICE has produced guidance on the components of good patient experience in adult NHS services. All healthcare professionals should follow NICE s recommendations on patient experience. See recommendations on shared decision making and information enabling people to actively participate in their care, tailoring healthcare services for each patient and continuity of care and relationships. See what NICE says on home care for older people.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148", "drug": {}}}, {"category": "treatment", "id": "t5886", "name": "storage and preparation of feeds", "draggable": "true", "value": {"name": "storage and preparation of feeds", "type": "treatment related", "time": "", "intention": "", "description": "title:storage and preparation of feedshead:Storage and preparation of feedssubhead:StorageFeeds should be stored according to the manufacturer s instructions and, where applicable, food hygiene legislation.Where ready-to-use feeds are not available, feeds may be prepared in advance, stored in a refrigerator, and used within 24 hours.subhead:PreparationWherever possible pre-packaged, ready-to-use feeds should be used in preference to feeds requiring decanting, reconstitution or dilution.The system selected should require minimal handling to assemble, and be compatible with the patient s enteral feeding tube. Effective hand decontamination must be carried out before starting feed preparation.When decanting, reconstituting or diluting feeds, prepare a clean working area and use equipment dedicated for enteral feed use only.Feeds should be mixed using cooled boiled water or freshly opened sterile water and a no-touch technique.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5924", "name": "possible complications", "draggable": "true", "value": {"name": "possible complications", "type": "treatment related", "time": "", "intention": "", "description": "title:possible complications", "drug": {}}}, {"category": "treatment", "id": "t5843", "name": "adult admitted to hospital", "draggable": "true", "value": {"name": "adult admitted to hospital", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:adult admitted to hospital", "drug": {}}}, {"category": "treatment", "id": "t5842", "name": "adult not admitted to hospital", "draggable": "true", "value": {"name": "adult not admitted to hospital", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:adult not admitted to hospital", "drug": {}}}, {"category": "treatment", "id": "t5905", "name": "hand decontamination", "draggable": "true", "value": {"name": "hand decontamination", "type": "treatment related", "time": "", "intention": "", "description": "title:hand decontaminationhead:Hand decontaminationHands must be decontaminated in all of the following circumstances:  immediately before every episode of direct patient contact or care, including aseptic procedures immediately after every episode of direct patient contact or care immediately after any exposure to body fluids immediately after any other activity or contact with a patient s surroundings that could potentially result in hands becoming contaminated immediately after removal of gloves.Decontaminate hands preferably with a handrub, conforming to current British standards (at the time of publication of the recommendations (March 2012): BS EN 1500:1997), except in the following circumstances, when liquid soap and water must be used: when hands are visibly soiled or potentially contaminated with body fluids or in clinical situations where there is potential for the spread of alcohol-resistant organisms (such as Clostridium difficile or other organisms that cause diarrhoeal illness).Healthcare workers should ensure that their hands can be decontaminated throughout the duration of clinical work by: being bare below the elbow when delivering direct patient care (bare below the elbow is considered to mean: not wearing false nails or nail polish; not wearing a wrist-watch or stoned rings; wearing short-sleeved garments or being able to roll or push up sleeves) removing wrist and hand jewellery making sure that fingernails are short, clean and free of nail polish covering cuts and abrasions with waterproof dressings.An effective handwashing technique involves three stages: preparation, washing and rinsing, and drying. For preparation, wet hands under tepid running water before applying liquid soap or an antimicrobial preparation. The handwash solution must come into contact with all of the surfaces of the hand. The hands must be rubbed together vigorously for a minimum of 10\u201315 seconds, paying particular attention to the tips of the fingers, the thumbs and the areas between the fingers. Rinse hands thoroughly before drying with good quality paper towels.When decontaminating hands using an alcohol handrub, ensure that hands are free from dirt and organic material. The handrub solution must come into contact with all surfaces of the hand. The hands must be rubbed together vigorously, paying particular attention to the tips of the fingers, the thumbs and the areas between the fingers, until the solution has evaporated and the hands are dry.An emollient hand cream should be applied regularly to protect skin from the drying effects of regular hand decontamination. If a particular soap, antimicrobial hand wash or alcohol product causes skin irritation an occupational health team should be consulted.Educate patients and carers about: the benefits of effective hand decontamination the correct techniques and timing of hand decontamination when it is appropriate to use liquid soap and water or handrub the availability of hand decontamination facilities their role in maintaining standards of healthcare workers  hand decontamination.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Infection prevention and control quality standard3Hand decontaminationSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5839", "name": "management", "draggable": "true", "value": {"name": "management", "type": "treatment related", "time": "", "intention": "", "description": "title:management", "drug": {}}}, {"category": "treatment", "id": "t5877", "name": "antibiotic prophylaxis", "draggable": "true", "value": {"name": "antibiotic prophylaxis", "type": "treatment related", "time": "", "intention": "", "description": "title:antibiotic prophylaxishead:Antibiotic prophylaxisGive antibiotic prophylaxis to patients before: clean surgery involving placing a prosthesis or implant clean-contaminated surgery contaminated surgery. Do not use antibiotic prophylaxis routinely for clean non-prosthetic uncomplicated surgery.Use the local antibiotic formulary and always consider potential adverse effects when choosing specific antibiotics for prophylaxis.Consider giving a single dose of antibiotic prophylaxis intravenously on starting anaesthesia. However, give prophylaxis earlier for operations in which a tourniquet is used.Before giving antibiotic prophylaxis, consider the timing and pharmacokinetics (for example, the serum half-life) and necessary infusion time of the antibiotic. Give a repeat dose of antibiotic prophylaxis when the operation is longer than the half-life of the antibiotic given.Give antibiotic treatment (in addition to prophylaxis) to patients having surgery on a dirty or infected wound.Inform patients before the operation, whenever possible, if they will need antibiotic prophylaxis, and afterwards if they have been given antibiotics during their operation.See what NICE says on antimicrobial stewardship.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Surgical site infection quality standard2Antibiotic prophylaxisSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG74", "drug": {}}}, {"category": "treatment", "id": "t5934", "name": "possible complications", "draggable": "true", "value": {"name": "possible complications", "type": "treatment related", "time": "", "intention": "", "description": "title:possible complications", "drug": {}}}, {"category": "treatment", "id": "t5832", "name": "tests and assessment", "draggable": "true", "value": {"name": "tests and assessment", "type": "treatment related", "time": "", "intention": "", "description": "title:tests and assessmenthead:Tests and assessmentsubhead:Initial tests and assessmentUndertake a urine dipstick test using an appropriately collected sample to test for the presence of blood, glucose, protein, leukocytes and nitrites. Appropriate urine samples include clean-catch midstream samples, samples taken from a freshly inserted intermittent sterile catheter or from a catheter port. Do not take samples from leg bags. If the dipstick test result and person s symptoms suggest an infection, arrange a urine bacterial culture and antibiotic sensitivity test before starting antibiotic treatment. Treatment need not be delayed but may be adapted when results are available.Be aware that bacterial colonisation will be present in people using a catheter and so urine dipstick testing and bacterial culture may be unreliable for diagnosing active infection.Ask people and/or their family members and carers to complete a  fluid input/urine output chart  to record fluid intake, frequency of urination and volume of urine passed for a minimum of 3 days.\tConsider measuring the urinary flow rate in people who are able to void voluntarily.Measure the post-void residual urine volume by ultrasound, preferably using a portable scanner, and consider taking further measurements on different occasions to establish how bladder emptying varies at different times and in different circumstances.Do not offer urodynamic investigations (such as filling cystometry and pressure-flow studies) routinely to people who are known to have a low risk of renal complications (for example, most people with multiple sclerosis).NICE has published a medtech innovation briefing on BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume.subhead:Assess the impact on families and carersAssess the impact of lower urinary tract symptoms on the person s family members and carers and consider ways of reducing any adverse impact. If it is suspected that severe stress is leading to abuse, follow local safeguarding procedures. subhead:Further assessment for people at high risk of renal complications Consider making a referral for a renal ultrasound scan in people who are at high risk of renal complications such as those with spina bifida or a spinal cord injury. Offer video-urodynamic investigations to people who are known to have a high risk of renal complications (for example, people with spina bifida, spinal cord injury or anorectal abnormalities). Quality standardsThe following quality statements are relevant to this part of the interactive flowchart.1Diagnosing urinary tract infections in adults aged 65 years and over2Diagnosing urinary tract infections in adults with catheters4Urine culture for adults with a urinary tract infection that does not respond to initial antibiotic treatment5Antibiotic treatment for asymptomatic adults with catheters and non-pregnant women6Antibiotic prophylaxis to prevent catheter-related urinary tract infectionSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148", "drug": {}}}, {"category": "treatment", "id": "t5834", "name": "management", "draggable": "true", "value": {"name": "management", "type": "treatment related", "time": "", "intention": "", "description": "title:management", "drug": {}}}, {"category": "treatment", "id": "t5863", "name": "assessment", "draggable": "true", "value": {"name": "assessment", "type": "treatment related", "time": "", "intention": "", "description": "title:assessment", "drug": {}}}, {"category": "treatment", "id": "t5893", "name": "catheter insertion", "draggable": "true", "value": {"name": "catheter insertion", "type": "treatment related", "time": "", "intention": "", "description": "title:catheter insertionhead:Catheter insertionAll catheterisations carried out by healthcare workers should be aseptic procedures. After training, healthcare workers should be assessed for their competence to carry out these types of procedures.Intermittent self-catheterisation is a clean procedure. A lubricant for single-patient use is required for non-lubricated catheters.Offer a choice of either single-use hydrophilic or gel reservoir catheters for intermittent self-catheterisation.For urethral catheterisation, the meatus should be cleaned before insertion of the catheter, in accordance with local guidelines/policy.An appropriate lubricant from a single-use container should be used during catheter insertion to minimise urethral trauma and infection. In general, inflate the catheter balloon with 10 ml of sterile water in adults and 3\u20135 ml in children.NICE has published medtech innovation briefings on:  Farco-fill Protect for indwelling urinary catheterisation Urethrotech UCD for difficult or failed catheterisation S-Cath System for suprapubic catheterisation.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Infection prevention and control quality standard4Urinary cathetersSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5900", "name": "device insertion site care", "draggable": "true", "value": {"name": "device insertion site care", "type": "treatment related", "time": "", "intention": "biopatch\nbiopatch (for the skin) is used to clean the skin to prevent infection that may be caused by surgery, injection, or skin injury.\nbiopatch may also be used for purposes not listed in this medication guide.", "description": "title:device insertion site carehead:Device insertion site careDecontaminate the skin at the insertion site with chlorhexidine gluconateIn 2012 a safety alert for chlorhexidine was issued related to the risk of adverse events. in 70% alcohol before inserting a peripheral vascular access device or a peripherally inserted central catheter.Use a sterile transparent semipermeable membrane dressing to cover the vascular access device insertion site.Consider a sterile gauze dressing covered with a sterile transparent semipermeable membrane dressing only if the patient has profuse perspiration, or if the vascular access device insertion site is bleeding or oozing. If a gauze dressing is used: change it every 24 hours, or sooner if it is soiled and replace it with a sterile transparent semipermeable membrane dressing as soon as possible.Change the transparent semipermeable membrane dressing covering a central venous access device insertion site every 7 days, or sooner if the dressing is no longer intact or moisture collects under it.Leave the transparent semipermeable membrane dressing applied to a peripheral cannula insertion site in situ for the life of the cannula, provided that the integrity of the dressing is retained.Dressings used on tunnelled or implanted central venous catheter sites should be replaced every 7 days until the insertion site has healed, unless there is an indication to change them sooner. Healthcare workers should ensure that catheter-site care is compatible with catheter materials (tubing, hubs, injection ports, luer connectors and extensions) and carefully check compatibility with the manufacturer s recommendations.Decontaminate the central venous catheter insertion site and surrounding skin during dressing changes using chlorhexidine gluconate in 70% alcohol, and allow to air dry. Consider using an aqueous solution of chlorhexidine gluconate if the manufacturer s recommendations prohibit the use of alcohol with their catheter.Individual sachets of antiseptic solution or individual packages of antiseptic-impregnated swabs or wipes should be used to disinfect the dressing site.NICE has published a medtech innovation briefing on Biopatch for venous or arterial catheter sites.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Infection prevention and control quality standard5Vascular access devicesSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5852", "name": "treatment to improve bladder storage", "draggable": "true", "value": {"name": "treatment to improve bladder storage", "type": "cancer ralated", "time": "", "intention": "", "description": "title:treatment to improve bladder storage", "drug": {}}}, {"category": "treatment", "id": "t5854", "name": "treatment to improve bladder emptying", "draggable": "true", "value": {"name": "treatment to improve bladder emptying", "type": "cancer ralated", "time": "", "intention": "", "description": "title:treatment to improve bladder emptyinghead:Treatment to improve bladder emptyingDo not offer alpha-blockers to people as a treatment for bladder emptying problems caused by neurological disease.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148", "drug": {}}}, {"category": "treatment", "id": "t5853", "name": "treatment for stress incontinence", "draggable": "true", "value": {"name": "treatment for stress incontinence", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:treatment for stress incontinence", "drug": {}}}, {"category": "treatment", "id": "t5887", "name": "administration of feeds", "draggable": "true", "value": {"name": "administration of feeds", "type": "treatment related", "time": "", "intention": "", "description": "title:administration of feedshead:Administration of feedsUse minimal handling and an aseptic technique to connect the administration system to the enteral feeding tube.Ready-to-use feeds may be given for a whole administration session, up to a maximum of 24 hours. Administer reconstituted feeds over a maximum 4-hour period.Administration sets and feed containers are for single use and must be discarded after each feeding session.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5847", "name": "acutely ill patients in hospital", "draggable": "true", "value": {"name": "acutely ill patients in hospital", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:acutely ill patients in hospital", "drug": {}}}, {"category": "treatment", "id": "t5844", "name": "monitoring in hospital", "draggable": "true", "value": {"name": "monitoring in hospital", "type": "treatment related", "time": "", "intention": "carbon dioxide\n", "description": "title:monitoring in hospitalhead:Monitoring in hospitalConsider measuring a baseline C-reactive protein concentration in patients with community-acquired pneumonia on admission to hospital, and repeat the test if clinical progress is uncertain after 48 to 72 hours.subhead:Severe acute respiratory failureNICE has published interventional procedures guidance on the following procedures with special arrangements for consent, audit and clinical governance: extracorporeal membrane carbon dioxide removal for acute respiratory failure extracorporeal membrane oxygenation for severe acute respiratory failure in adults.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG191", "drug": {}}}, {"category": "treatment", "id": "t5846", "name": "patient information", "draggable": "true", "value": {"name": "patient information", "type": "treatment related", "time": "", "intention": "", "description": "title:patient informationhead:Patient informationExplain to patients with community-acquired pneumonia that after starting treatment their symptoms should steadily improve, although the rate of improvement will vary with the severity of the pneumonia, and most people can expect that by: 1 week: fever should have resolved 4 weeks: chest pain and sputum production should have substantially reduced 6 weeks: cough and breathlessness should have substantially reduced  3 months: most symptoms should have resolved but fatigue may still be present  6 months: most people will feel back to normal. Advise patients with community-acquired pneumonia to consult their healthcare professional if they feel that their condition is deteriorating or not improving as expected.NICE has written information for the public on pneumonia. SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG191", "drug": {}}}, {"category": "treatment", "id": "t5906", "name": "personal protective equipment", "draggable": "true", "value": {"name": "personal protective equipment", "type": "treatment related", "time": "", "intention": "", "description": "title:personal protective equipmenthead:Personal protective equipmentIn accordance with current health and safety legislation, selection of protective equipment must be based on an assessment of the risk of transmission of microorganisms to the patient, and the risk of contamination of the healthcare worker s clothing and skin by patients  blood, body fluids, secretions or excretions.Current health and safety legislation includes (at the time of publication of the recommendations [March 2012]): Health and Safety at Work Act 1974, Management of Health and Safety at Work Regulations 1999, Health and Safety Regulations 2002, Control of Substances Hazardous to Health Regulations 2002, Personal Protective Equipment Regulations 2002 and Health and Social Care Act 2008.subhead:Hand protectionGloves used for direct patient care: must conform to current EU legislation (CE marked as medical gloves for single use; at the time of publication of the recommendations (March 2012): BS EN 455 Parts 1-4 Medical gloves for single use) and  should be appropriate for the task.In accordance with current health and safety legislation, gloves must be worn for invasive procedures, contact with sterile sites and non-intact skin or mucous membranes, and all activities that have been assessed as carrying a risk of exposure to blood, body fluids, secretions or excretions, or to sharp or contaminated instruments.Gloves must be worn as single-use items, in accordance with current health and safety legislation. They must be put on immediately before an episode of patient contact or treatment and removed as soon as the activity is completed. Gloves must be changed between caring for different patients, and between different care or treatment activities for the same patient.Ensure that gloves used for direct patient care that have been exposed to body fluids are disposed of correctly, in accordance with current national legislation (for guidance, see (at the time of publication of the recommendations [March 2012]): Safe management of healthcare waste (2011)) or local policies (see waste disposal).Alternatives to natural rubber latex gloves must be available for patients, carers and healthcare workers who have a documented sensitivity to natural rubber latex.Do not use polythene gloves for clinical interventions.subhead:Body protectionWhen delivering direct patient care: wear a disposable plastic apron if there is a risk that clothing may be exposed to blood, body fluids, secretions or excretions or  wear a long-sleeved fluid-repellent gown if there is a risk of extensive splashing of blood, body fluids, secretions or excretions onto skin or clothing.When using disposable plastic aprons or gowns: use them as single-use items, for one procedure or one episode of direct patient care and ensure they are disposed of correctly (see waste disposal).subhead:Face and eye protection:Face masks and eye protection must be worn where there is a risk of blood, body fluids, secretions or excretions splashing into the face and eyes, in accordance with current health and safety legislation.Respiratory protective equipment, for example a particulate filter mask, must be used when clinically indicated in accordance with current health and safety legislation.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5878", "name": "maintenance of homeostasis", "draggable": "true", "value": {"name": "maintenance of homeostasis", "type": "treatment related", "time": "", "intention": "", "description": "title:maintenance of homeostasishead:Maintenance of homeostasisMaintain patient temperature in line with NICE s recommendations on inadvertent perioperative hypothermia.Maintain optimal oxygenation during surgery. In particular, give patients sufficient oxygen during major surgery and in the recovery period to ensure that a haemoglobin saturation of more than 95% is maintained.Maintain adequate perfusion during surgery. Do not give insulin routinely to patients who do not have diabetes to optimise blood glucose postoperatively as a means of reducing the risk of surgical site infection.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Surgical site infection quality standard3Patient temperatureSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG74", "drug": {}}}, {"category": "treatment", "id": "t5935", "name": "monitoring and surveillance", "draggable": "true", "value": {"name": "monitoring and surveillance", "type": "treatment related", "time": "", "intention": "", "description": "title:monitoring and surveillancehead:Monitoring and surveillance subhead:Monitoring renal functionDo not rely on serum creatinine and estimated glomerular filtration rate in isolation for monitoring renal function in people with neurogenic lower urinary tract dysfunction.Consider using isotopic glomerular filtration rate when an accurate measurement of glomerular filtration rate is required (for example, if imaging of the kidneys suggests that renal function might be compromised).For more information on the measurement of kidney function, see what NICE says on chronic kidney disease. subhead:SurveillanceOffer lifelong ultrasound surveillance of the kidneys to people who are judged to be at high risk of renal complications (for example, consider surveillance ultrasound scanning at annual or 2 yearly intervals). Those at high risk include people with spinal cord injury or spina bifida and those with adverse features on urodynamic investigations such as impaired bladder compliance, detrusor-sphincter dyssynergia or vesico-ureteric reflux.Consider the need for continuing upper urinary tract surveillance in people who have impaired bladder storage (for example, due to reduced bladder compliance). Consider urodynamic investigations as part of a surveillance regimen for people at high risk of urinary tract complications (for example, people with spina bifida, spinal cord injury or anorectal abnormalities).Do not use plain abdominal radiography for routine surveillance in people with neurogenic lower urinary tract dysfunction.Do not use cystoscopy for routine surveillance in people with neurogenic lower urinary tract dysfunction.Do not use renal scintigraphy for routine surveillance in people with neurogenic lower urinary tract dysfunction.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148", "drug": {}}}, {"category": "treatment", "id": "t5864", "name": "management", "draggable": "true", "value": {"name": "management", "type": "treatment related", "time": "", "intention": "", "description": "title:management", "drug": {}}}, {"category": "treatment", "id": "t5894", "name": "catheter drainage", "draggable": "true", "value": {"name": "catheter drainage", "type": "treatment related", "time": "", "intention": "", "description": "title:catheter drainagehead:Catheter drainageIn patients for whom it is appropriate, a catheter valve may be used as an alternative to a drainage bag.Indwelling catheters should be connected to a sterile closed urinary drainage system or catheter valve.Urinary drainage bags should be positioned below the level of the bladder, and should not be in contact with the floor. A link system should be used to facilitate overnight drainage, to keep the original system intact.NICE has published a medtech innovation briefing on the U-Drain for people needing night drainage of urine or dialysis fluid.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Infection prevention and control quality standard4Urinary cathetersSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5901", "name": "device management", "draggable": "true", "value": {"name": "device management", "type": "treatment related", "time": "", "intention": "chlorhexidine\nchlorhexidine is used to treat gingivitis. it helps to reduce the inflammation (redness) and swelling of your gums and to reduce gum bleeding.\nalthough certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. in these cases, your doctor may want to change the dose, or other precautions may be necessary. tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [otc]) medicine.\nthe cap on the original container of chlorhexidine can be used to measure the 15 ml (\u00bd fluid ounce) dose of chlorhexidine. fill the cap to the ``fill line.   if you do not receive the dental rinse in its original container, make sure you have a measuring device to measure out the correct dose. your pharmacist can help you with this.", "description": "title:device managementhead:Device managementDecontaminate the injection port or vascular access device catheter hub before and after accessing the system using chlorhexidine gluconateIn 2012 a safety alert for chlorhexidine was issued related to the risk of adverse events. in 70% alcohol. Consider using an aqueous solution of chlorhexidine gluconate if the manufacturer s recommendations prohibit the use of alcohol with their catheter.In-line filters should not be used routinely for infection prevention.Antibiotic lock solutions should not be used routinely to prevent CRBSI.Systemic antimicrobial prophylaxis should not be used routinely to prevent catheter colonisation or CRBSI, either before insertion or during the use of a central venous catheter.Preferably, a single lumen catheter should be used to administer parenteral nutrition. If a multilumen catheter is used, one port must be exclusively dedicated for total parenteral nutrition, and all lumens must be handled with the same meticulous attention to aseptic technique.Preferably, a sterile 0.9 percent sodium chloride injection should be used to flush and lock catheter lumens.When recommended by the manufacturer, implanted ports or opened-ended catheter lumens should be flushed and locked with heparin sodium flush solutions. Systemic anticoagulants should not be used routinely to prevent CRBSI.If needleless devices are used, the manufacturer s recommendations for changing the needleless components should be followed.When needleless devices are used, healthcare workers should ensure that all components of the system are compatible and secured, to minimise leaks and breaks in the system.When needleless devices are used, the risk of contamination should be minimised by decontaminating the access port with either alcohol or an alcoholic solution of chlorhexidine gluconate before and after using it to access the system. In general, administration sets in continuous use need not be replaced more frequently than at 72-hour intervals unless they become disconnected or a catheter-related infection is suspected or documented.Administration sets for blood and blood components should be changed every 12 hours, or according to the manufacturer s recommendations. Administration sets used for total parenteral nutrition infusions should generally be changed every 24 hours. If the solution contains only glucose and amino acids, administration sets in continuous use do not need to be replaced more frequently than every 72 hours.Avoid the use of multidose vials, in order to prevent the contamination of infusates.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Infection prevention and control quality standard5Vascular access devicesSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5855", "name": "management with catheter valves", "draggable": "true", "value": {"name": "management with catheter valves", "type": "information and support", "time": "", "intention": "", "description": "title:management with catheter valveshead:Management with catheter valvesIn people for whom it is appropriate, a catheter valve may be used as an alternative to a drainage bag.To ensure that a catheter valve is appropriate, take into consideration the person s preference, family member and carer support, manual dexterity, cognitive ability, and lower urinary tract function when offering a catheter valve as an alternative to continuous drainage into a bag.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG148CG139", "drug": {}}}, {"category": "treatment", "id": "t5888", "name": "care of insertion site and enteral feeding tube", "draggable": "true", "value": {"name": "care of insertion site and enteral feeding tube", "type": "treatment related", "time": "", "intention": "", "description": "title:care of insertion site and enteral feeding tubehead:Care of insertion site and enteral feeding tubeThe stoma should be washed daily with water and dried thoroughly.To prevent blockages, flush the enteral feeding tube before and after feeding or administering medications using single-use syringes or single-patient-use (reusable) syringes according to the manufacturer s instructions. Use: freshly drawn tap water for patients who are not immunosuppressed either cooled freshly boiled water or sterile water from a freshly opened container for patients who are immunosuppressed.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5845", "name": "safe discharge from hospital", "draggable": "true", "value": {"name": "safe discharge from hospital", "type": "treatment related", "time": "", "intention": "", "description": "title:safe discharge from hospitalhead:Safe discharge from hospitalDo not routinely discharge patients with community-acquired pneumonia if in the past 24 hours they have had 2 or more of the following findings: temperature higher than 37.5\u00b0C  respiratory rate 24 breaths per minute or more heart rate over 100 beats per minute  systolic blood pressure 90 mmHg or less oxygen saturation under 90% on room air abnormal mental status inability to eat and drink without assistance.Consider delaying discharge for patients with community-acquired pneumonia if their temperature is higher than 37.5\u00b0C.Also see discharge vulnerable people from health or social care settings to a warm home in excess winter deaths and illnesses associated with cold homes.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG191", "drug": {}}}, {"category": "treatment", "id": "t5907", "name": "waste disposal", "draggable": "true", "value": {"name": "waste disposal", "type": "treatment related", "time": "", "intention": "", "description": "title:waste disposalhead:Waste disposalHealthcare waste must be segregated immediately by the person generating the waste into appropriate colour-coded storage or waste disposal bags or containers defined as being compliant with current national legislation and local policies.Healthcare waste must be labelled, stored, transported and disposed of in accordance with current national legislation and local policies.For guidance on current national legislation see (at the time publication of the recommendations [March 2012]): Safe management of healthcare waste (2011).Educate patients and carers about the correct handling, storage and disposal of healthcare waste.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5879", "name": "surgical incision", "draggable": "true", "value": {"name": "surgical incision", "type": "treatment related", "time": "", "intention": "chlorhexidine\nchlorhexidine is used to treat gingivitis. it helps to reduce the inflammation (redness) and swelling of your gums and to reduce gum bleeding.\nalthough certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. in these cases, your doctor may want to change the dose, or other precautions may be necessary. tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [otc]) medicine.\nthe cap on the original container of chlorhexidine can be used to measure the 15 ml (\u00bd fluid ounce) dose of chlorhexidine. fill the cap to the ``fill line.   if you do not receive the dental rinse in its original container, make sure you have a measuring device to measure out the correct dose. your pharmacist can help you with this.", "description": "title:surgical incisionhead:Surgical incision Do not use non-iodophor-impregnated incise drapes routinely for surgery as they may increase the risk of surgical site infection.If an incise drape is required, use an iodophor-impregnated drape unless the patient has an iodine allergy.Prepare the skin at the surgical site immediately before incision using an antiseptic (aqueous or alcohol-based) preparation: povidone-iodine or chlorhexidine are most suitable.If diathermy is to be used, ensure that antiseptic skin preparations are dried by evaporation and pooling of alcohol-based preparations is avoided.Do not use diathermy for surgical incision to reduce the risk of surgical site infection.subhead:Creutzfeldt\u2013Jakob diseaseNICE has published interventional procedures guidance on patient safety and reduction of risk of transmission of Creutzfeldt\u2013Jakob disease (CJD) via interventional procedures.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG74", "drug": {}}}, {"category": "treatment", "id": "t5895", "name": "catheter maintenance", "draggable": "true", "value": {"name": "catheter maintenance", "type": "treatment related", "time": "", "intention": "", "description": "title:catheter maintenancehead:Catheter maintenanceHealthcare workers should ensure that the connection between the catheter and the urinary drainage system is not broken except for good clinical reasons (for example changing the bag in line with the manufacturer s recommendations).Healthcare workers must decontaminate their hands and wear a new pair of clean, non-sterile gloves before manipulating a patient s catheter, and must decontaminate their hands after removing gloves.Urine samples must be obtained from a sampling port using an aseptic technique.The urinary drainage bag should be emptied frequently enough to maintain urine flow and prevent reflux, and should be changed when clinically indicated.The meatus should be washed daily with soap and water. To minimise the risk of blockages, encrustations and catheter-associated infections for patients with a long-term indwelling urinary catheter: develop a patient-specific care regimen consider approaches such as reviewing the frequency of planned catheter changes and increasing fluid intake document catheter blockages.Bladder instillations or washouts must not be used to prevent catheter-associated infections.Catheters should be changed only when clinically necessary or according to the manufacturer s current recommendations.When changing catheters in patients with a long-term indwelling urinary catheter: do not offer antibiotic prophylaxis routinely consider antibiotic prophylaxisAt the time of publication of the recommendations (March 2012), no antibiotics have a UK marketing authorisation for this indication. Informed consent should be obtained and documented. for patients who: have a history of symptomatic urinary tract infection after catheter change or experience trauma during catheterisation (trauma is defined as frank haematuria after catheterisation or two or more attempts of catheterisation).See what NICE says on antimicrobial stewardship.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Infection prevention and control quality standard4Urinary cathetersSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5908", "name": "safe use and disposal of sharps", "draggable": "true", "value": {"name": "safe use and disposal of sharps", "type": "treatment related", "time": "", "intention": "", "description": "title:safe use and disposal of sharpshead:Safe use and disposal of sharpsSharps should not be passed directly from hand to hand, and handling should be kept to a minimum. (This recommendation contains  should  rather than  must  because this is not considered to be covered by legislation.)Used standard needles:  must not be bent or broken before disposal (it is acceptable to bend needles when they are part of an approved sharps safety device) must not be recapped.In dentistry, if recapping or disassembly is unavoidable, a risk assessment must be undertaken and appropriate safety devices should be used (see Health and Safety (Sharp Instruments in Healthcare) Regulations 2013).Used sharps must be discarded immediately by the person generating the sharps waste into a sharps container conforming to current standards (at the time of publication of the recommendations (March 2012), current standards are UN3291 and BS 7320).Sharps containers: must be located in a safe position that avoids spillage, is at a height that allows the safe disposal of sharps, is away from public access areas and is out of the reach of children  must not be used for any other purpose than the disposal of sharps must not be filled above the fill line must be disposed of when the fill line is reached should be temporarily closed when not in use should be disposed of every 3 months even if not full, by the licensed route in accordance with local policy.For guidance see (at the time of publication of the recommendations [March 2012]): Safe management of healthcare waste (2011).Use sharps safety devices if a risk assessment has indicated that they will provide safer systems of working for healthcare workers, carers and patients.Train and assess all users in the correct use and disposal of sharps and sharps safety devices.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG139", "drug": {}}}, {"category": "treatment", "id": "t5910", "name": "preventing infection related to enteral feeding", "draggable": "true", "value": {"name": "preventing infection related to enteral feeding", "type": "treatment related", "time": "", "intention": "", "description": "title:preventing infection related to enteral feeding", "drug": {}}}, {"category": "treatment", "id": "t5911", "name": "preventing infection related to vascular access devices", "draggable": "true", "value": {"name": "preventing infection related to vascular access devices", "type": "treatment related", "time": "", "intention": "", "description": "title:preventing infection related to vascular access devices", "drug": {}}}, {"category": "treatment", "id": "t5909", "name": "preventing infection related to long term urinary catheter", "draggable": "true", "value": {"name": "preventing infection related to long term urinary catheter", "type": "treatment related", "time": "", "intention": "", "description": "title:preventing infection related to long-term urinary catheter", "drug": {}}}, {"category": "drug", "id": "d140", "name": "cefotaxime", "draggable": "true", "value": {"name": "cefotaxime", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d142", "name": "ceftaroline fosamil", "draggable": "true", "value": {"name": "ceftaroline fosamil", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d144", "name": "ceftriaxone", "draggable": "true", "value": {"name": "ceftriaxone", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d37", "name": "amoxicillin", "draggable": "true", "value": {"name": "amoxicillin", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d145", "name": "cefuroxime", "draggable": "true", "value": {"name": "cefuroxime", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d46", "name": "antifungal", "draggable": "true", "value": {"name": "antifungal", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d130", "name": "carbon dioxide", "draggable": "true", "value": {"name": "carbon dioxide", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d278", "name": "excel", "draggable": "true", "value": {"name": "excel", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d151", "name": "chlorhexidine", "draggable": "true", "value": {"name": "chlorhexidine", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d92", "name": "biopatch", "draggable": "true", "value": {"name": "biopatch", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d331", "name": "heparin sodium", "draggable": "true", "value": {"name": "heparin sodium", "time": "None", "period": "None", "dosage": "None"}}]}